Table 2 Shantha's Product Pipeline (2009)
From: Indian vaccine innovation: the case of Shantha Biotechnics
Product Description | Development Stage | Development Partners |
|---|---|---|
Vaccines | Â | Â |
Hepatitis B (Shanvac-B) | On market since 1997, post-marketing survey in progress | CCMB (India) |
Japanese Encephalitis (Jencevac) | On market | Green Cross Vaccine Corporation (Korea) |
Hib (ShanHib) | On market | Berna Biotech (Switzerland) |
Rotavirus | Preclinical | NIH, Bill and Melinda Gates Foundation, PATH |
Varicella | Preclinical | NIH |
Dengue | Preclinical | Inviragen, CDC |
HPV | Preclinical | NIH, NCI, John's Hopkins University |
Pneumococcal | R&D | PATH |
Meningococcal A (Intervax) | On market | Intervax Biologics (Canada) |
Meningococcal C (Intervax) | On market | Intervax Biologics (Canada) |
Cholera (oral) | Clinical trials | International Vaccine Institute, Korea |
Typhoid | Clinical trials | International Vaccine Institute, Korea |
Combination Vaccines | Â | Â |
MMR | R&D | - |
DPT | On market | - |
Shantetra: DPT, Hep B | On market | - |
ShanHib-DPT: Hib, DPT | On market | - |
Shan5: DPT, Hep B, Hib | On market | - |
DPT, Hep B, influenza | Was expected on market 2009 | - |
Monoclonal Antibodies | Â | Â |
Lung cancer | Preclinical | - |
Melanoma | Preclinical | - |
Cocktail | R&D | - |
Bio-therapeutics | Â | Â |
Interferon α 2b (Shanferon) | On market | - |
Erythropoietin (Shanpoietin) | On market (launched 2005) | - |
Streptokinase (Shankinase) | On market - discontinued | - |
Insulin | On market | Biocon |
GCSF | Clinical trials | - |
Diagnostics | Â | Â |
Hepatitis B | On market | - |
Cancer (α-feto protein) | On market | - |